entertainment -WSS

entertainment

author：leisure time 2025-10-02 22:56:10 - browse：748

A collage illustration with a patient in the center with a hand to the left administering treatment and a doctor in the background. -- health tech coverage from STAT — Katy Lemay for STAT

The makers of minimally invasive surgical devices seemed poised to capture a wide swath of the obesity treatment market. Patients needed an option that lay between the two treatment extremes: cutting open the abdomen to perform permanent bariatric surgery, or changing your diet or exercise routine.

Then, a new class of weight loss medications that successfully mimic the feeling of fullness hit the market, and the landscape changed.

“It turns out that what came along — before those endoscopic devices have really matured — is these new drugs,” said Lee Kaplan, director of Massachusetts General’s obesity institute. Since the Food and Drug Administration approved Novo Nordisk’s Wegovy in 2021, it and similar drugs that followed have swiftly captured the public’s interest — and are on their way to generating billions of dollars in sales.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Pharmacists can make shortage drugs, but at what cost?

focus

WSS

How climate

Hospital price transparency does save money, advocate argues

Report captures long Covid’s disabling effects and policy challenges

Cigna wins case to block Amy Bricker's move to CVS

California wildfire smoke linked to 52,000 early deaths, study says

Moderna says combo Covid

focus

entertainment

knowledge

Heart attack and stroke risk calculators need revising

Cigna wins case to block Amy Bricker's move to CVS

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

STAT Summit: How a Chicago ER doctor tackles gun violence

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pharmacists can make shortage drugs, but at what cost?

Apple is now the first public company to be valued at $3 trillion

STAT Summit: Biotech founders on deal

Medical records are filled with copy

FDA warns J&J's Abiomed: We will regulate your software

knowledge

NIH tests clinical research in primary care with $30 million program

Deposition: Sackler embraced plan to conceal OxyContin’s strength

STAT Summit: Michael J. Fox on progress in Parkinson's research

How faith leaders like me can help address America's obesity epidemic

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Deposition: Sackler embraced plan to conceal OxyContin’s strength

focus

leisure time

focus

knowledge